The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon(Amgen (United States)), Karen Rex(Amgen (United States)), Anne Y. Saiki(Amgen (United States)), Christopher Mohr(Amgen (United States)), Keegan S. Cooke(Amgen (United States)), Dhanashri Bagal(Amgen (United States)), Kevin Gaida(Amgen (United States)), Tyler Holt(Amgen (United States)), Charles G. Knutson(Amgen (United States)), Neelima Koppada(Amgen (United States)), Brian A. Lanman(Amgen (United States)), Jonathan Werner(Amgen (United States)), Aaron S. Rapaport(Amgen (United States)), Tisha San Miguel(Amgen (United States)), Roberto Ortiz(Amgen (United States)), Tao Osgood(Amgen (United States)), Ji-Rong Sun(Amgen (United States)), Xiaochun Zhu(Amgen (United States)), John D. McCarter(Amgen (United States)), Laurie P. Volak(Amgen (United States)), Brett E. Houk(Amgen (United States)), Marwan Fakih(City of Hope), Bert H. O’Neil(Indiana University School of Medicine), Timothy Price(Queen Elizabeth Hospital), Gerald S. Falchook(Sarah Cannon), Jayesh Desai(Peter MacCallum Cancer Centre), James Kuo, Ramaswamy Govindan(Washington University in St. Louis), David S. Hong(The University of Texas MD Anderson Cancer Center), Wenjun Ouyang(Amgen (United States)), Haby Henary(Amgen (United States)), Tara Arvedson(Amgen (United States)), Victor J. Cee(Amgen (United States)), J. Russell Lipford(Amgen (United States))
Cited by 2,242
Abstract
Related Papers
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al.|New England Journal of Medicine|2014|2.6k